The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
Bolstering neuroscience push with late-stage Tourette therapy
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The program expected to commence in August 2026 will be offered across multiple specialised areas with an intake of 20-30 students per course
A total of 300 transgender individuals were screened as part of the study, with 82 identified as high-risk due to symptoms of anxiety, depression, and self-harm or suicidal tendencies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
